This study aims to evaluate the efficacy and safety of intradermal injection of autologous stromal vascular fraction (SVF) in the treatment of atrophic acne scars. SVF is a heterogeneous cell population derived from adipose tissue, containing various regenerative and immunomodulatory cells, including mesenchymal stem cells, endothelial progenitor cells, and pericytes. In this prospective, randomized, split-face clinical trial, participants with atrophic acne scars will receive SVF injections on one side of the face and normal saline (NS) injections on the contralateral side as a control. Clinical efficacy will be assessed through blinded scar counts, digital imaging, and histological evaluations including epidermal and dermal regenerative markers. The study is designed to investigate whether SVF provides superior clinical improvement compared to placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
16
Autologous stromal vascular fraction (SVF) isolated from adipose tissue was injected intradermally into one side of the face to evaluate its efficacy in treating atrophic acne scars. SVF was freshly prepared on the same day of injection using enzymatic digestion and centrifugation.
Normal saline (NS) was injected intradermally into the contralateral side of the face and served as a placebo comparator to SVF in this split-face study on atrophic acne scars.
Change in total number of atrophic acne scars from baseline to Week 5
Time frame: Baseline and 5 weeks after treatment
Change in total number of atrophic acne scars from baseline to Week 10
Time frame: Baseline and 10 weeks after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.